2,6,10,14,19,23-Hexamethyl-25-<2,6,6-trimethyl-cyclohexen-(1)-yl>-pentacosadodecaen-(2,4,6,8,10,12,14,16,18,20,22,24)-saeure-methylester | 20186-11-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 2,6,10,14,19,23-Hexamethyl-25-<2,6,6-trimethyl-cyclohexen-(1)-yl>-pentacosadodecaen-(2,4,6,8,10,12,14,16,18,20,22,24)-saeure-methylester
• 英文别名: all-trans-2,6,10,14,19,23-Hexamethyl-25-(2,6,6-trimethyl-cyclohex-1-enyl)-pentacosa-2,4,6,8,10,12,14,16,18,20,22,24-dodecaen-1-saeure-methylester；(1'E,3'E)-3',4'-didehydro-β,ψ-caroten-16'-oic acid methyl ester；(1'E,3'E)-3',4'-Didehydro-β,ψ-carotin-16'-saeure-methylester；Torularhodin-methylester；Torularhodin methyl ester；methyl (2E,4E,6E,8E,10E,12E,14E,16E,18E,20E,22E,24E)-2,6,10,14,19,23-hexamethyl-25-(2,6,6-trimethylcyclohexen-1-yl)pentacosa-2,4,6,8,10,12,14,16,18,20,22,24-dodecaenoate
• CAS: 20186-11-2
• 化学式: C₄₁H₅₄O₂
• 分子量: 578.879
• InChiKey: BEFVBSDJQFOALN-AJOVAGQGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  13.6
• 重原子数：
  43
• 可旋转键数：
  14
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.34
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,6,10,14,19,23-Hexamethyl-25-<2,6,6-trimethyl-cyclohexen-(1)-yl>-pentacosadodecaen-(2,4,6,8,10,12,14,16,18,20,22,24)-saeure-methylester 生成 红酵母红素
  参考文献：
  名称：

  Testing the requirements of stages of physical activity among adults: The comparative effectiveness of stage-matched, mismatched, standard care, and control interventions

  摘要：

  We tested the comparative efficacy of 4 interventions to increase the physical activity behavior of college personnel randomly assigned to one condition (N = 196, 74% female, M age = 43.4 years) for 16 weeks. Stage-matched and mismatched interventions were developed based on the stages of change from the Transtheoretical Model and were contrasted with standard care (action-oriented) and control interventions to test the requirements of a true stage behavior Repeated measures of multivariate analyses of covariance indicated that the stage-matched and standard care interventions resulted in greater levels of both total and lifestyle physical activity compared with the mismatched and control interventions. The results supported the requirements of a stage behavior as defined by Weinstein, Rothman, and Sutton (1) and the superiority of the stage-matched intervention versus the mismatched intervention. However, the standard care intervention performed as well as the matched intervention, suggesting the need for further investigation. The results are discussed with respect to the high proportion of individuals in the action-oriented stages and previous research findings in the smoking literature.

  DOI：

  10.1207/s15324796abm2403_03
• 作为产物：
  描述：

  all-trans-2,6,10,14,19,23-Hexamethyl-25-(2,6,6-trimethyl-cyclohex-1-enyl)-pentacosa-2,4,6,8,10,12,14,18,20,22,24-dodecaen-16-in-1-saeure-methylester 在 喹啉 、 Lindlar's catalyst 、 甲苯 作用下， 生成 2,6,10,14,19,23-Hexamethyl-25-<2,6,6-trimethyl-cyclohexen-(1)-yl>-pentacosadodecaen-(2,4,6,8,10,12,14,16,18,20,22,24)-saeure-methylester
  参考文献：
  名称：

  Testing the requirements of stages of physical activity among adults: The comparative effectiveness of stage-matched, mismatched, standard care, and control interventions

  摘要：

  We tested the comparative efficacy of 4 interventions to increase the physical activity behavior of college personnel randomly assigned to one condition (N = 196, 74% female, M age = 43.4 years) for 16 weeks. Stage-matched and mismatched interventions were developed based on the stages of change from the Transtheoretical Model and were contrasted with standard care (action-oriented) and control interventions to test the requirements of a true stage behavior Repeated measures of multivariate analyses of covariance indicated that the stage-matched and standard care interventions resulted in greater levels of both total and lifestyle physical activity compared with the mismatched and control interventions. The results supported the requirements of a stage behavior as defined by Weinstein, Rothman, and Sutton (1) and the superiority of the stage-matched intervention versus the mismatched intervention. However, the standard care intervention performed as well as the matched intervention, suggesting the need for further investigation. The results are discussed with respect to the high proportion of individuals in the action-oriented stages and previous research findings in the smoking literature.

  DOI：

  10.1207/s15324796abm2403_03

文献信息

• Hydroxylated nebivolol metabolites
  申请人：O'Donnell P. John

  公开号：US20070014733A1

  公开（公告）日：2007-01-18

  Hydroxylated nebivolol metabolites increase NO release from human endothelial cell preparations in a concentration dependent fashion following acute administration. In addition, hydroxylated nebivolol metabolites, including but not limited to 4-hydroxy-6,6′difluoro-, 4-hydroxy-5-phenol-6,6′difluoro-, and 4-hydroxy-8-pheno-6,6′difluoro-, have the ability to increase the capacity for NO release in human endothelial cells following chronic administration. This invention provides hydroxylated nebivolol metabolites and compositions comprising nebivolol and/or at least one hydroxylated metabolite of nebivolol and/or at least one additional compound used to treat cardiovascular diseases or a pharmaceutically acceptable salt thereof. In addition, this invention provides methods of treating and/or preventing vascular diseases by administering at least one hydroxylated metabolite of nebivolol that is capable of releasing a therapeutically effective amount of nitric oxide to a targeted site affected by the vascular disease. Also, this invention is directed to the treatment and/or prevention of migraine headaches administering at least one hydroxylated metabolite of nebivolol. This invention may also be used in conjunction with or as a single treatment of metabolic syndrome disorders.

  羟基化奈必洛尔代谢物在急性给药后以浓度依赖性方式增加人内皮细胞制剂的一氧化氮释放。此外，羟基化奈必洛尔代谢物，包括但不限于4-羟基-6,6'-二氟代-、4-羟基-5-苯酚-6,6'-二氟代-和4-羟基-8-苯并-6,6'-二氟代-，在慢性给药后能够增加人内皮细胞的一氧化氮释放能力。本发明提供了羟基化奈必洛尔代谢物和包含奈必洛尔和/或至少一种羟基化奈必洛尔代谢物和/或至少一种用于治疗心血管疾病的附加化合物的组合物，以及可药用的盐。此外，本发明还提供了通过给药至少一种能够释放治疗有效量的一氧化氮到受血管疾病影响的靶向部位的羟基化奈必洛尔代谢物来治疗和/或预防血管疾病的方法。本发明还涉及通过给药至少一种羟基化奈必洛尔代谢物来治疗和/或预防偏头痛。本发明还可以与治疗代谢综合征障碍的其他治疗联合使用，或作为单一治疗。
• Dehydro-lycopin, ein Carotinoidfarbstoff mit 15 konjugierten Doppelbindungen
  作者：P. Karrer、J. Rustschmann

  DOI：10.1002/hlca.194502801116

  日期：——

  No abstract is available for this article.

  本文没有摘要。
• Glucuronidated nebivolol metabolites
  申请人：O'Donnell P. John

  公开号：US20070014734A1

  公开（公告）日：2007-01-18

  This invention provides glucuronidated nebivolol metabolites and pharmaceutical compositions of glucuronidated nebivolol metabolites for treatment of cardiovascular diseases. In addition, this invention also provides compositions comprising nebivolol and/or at least one glucuronidated metabolite of nebivolol and/or at least one other active compound in a pharmaceutically acceptable carrier. This invention also provides methods of treating and/or preventing vascular diseases, by administering at least one glucuronidated metabolite of nebivolol that is capable of releasing a therapeutically effective amount of nitric oxide to a targeted site affected by the vascular disease. Also, this invention is directed to the treatment and/or prevention of migraine headaches administering at least one glucuronidated metabolite of nebivolol. This invention may also be used in conjunction with or as a single treatment of metabolic syndrome disorders.

  这项发明提供了葡萄糖醛酸化的尼布ivolol代谢物以及用于治疗心血管疾病的葡萄糖醛酸化的尼布ivolol代谢物的制药组合物。此外，该发明还提供了包含尼布ivolol和/或至少一种尼布ivolol的葡萄糖醛酸化代谢物和/或至少一种其他活性化合物的药用可接受载体的组合物。该发明还提供了通过向受影响血管疾病的靶位点投与至少一种能释放治疗有效量一氧化氮的尼布ivolol的葡萄糖醛酸化代谢物来治疗和/或预防血管疾病的方法。此外，该发明旨在通过投与至少一种尼布ivolol的葡萄糖醛酸化代谢物来治疗和/或预防偏头痛。该发明还可与代谢综合征紊乱的单一治疗或联合治疗一起使用。
• HYDROXYLATED NEBIVOLOL METABOLITES
  申请人：O'Donnell John P.

  公开号：US20110065783A1

  公开（公告）日：2011-03-17

  Hydroxylated nebivolol metabolites increase NO release from human endothelial cell preparations in a concentration dependent fashion following acute administration. In addition, hydroxylated nebivolol metabolites, including but not limited to 4-hydroxy-6,6′difluoro-, 4-hydroxy-5-phenol-6,6′difluoro-, and 4-hydroxy-8-pheno-6,6′difluoro-, have the ability to increase the capacity for NO release in human endothelial cells following chronic administration. This invention provides hydroxylated nebivolol metabolites and compositions comprising nebivolol and/or at least one hydroxylated metabolite of nebivolol and/or at least one additional compound used to treat cardiovascular diseases or a pharmaceutically acceptable salt thereof. In addition, this invention provides methods of treating and/or preventing vascular diseases by administering at least one hydroxylated metabolite of nebivolol that is capable of releasing a therapeutically effective amount of nitric oxide to a targeted site affected by the vascular disease. Also, this invention is directed to the treatment and/or prevention of migraine headaches administering at least one hydroxylated metabolite of nebivolol. This invention may also be used in conjunction with or as a single treatment of metabolic syndrome disorders.

  羟基化的内比洛尔代谢物在急性给药后以浓度依赖的方式增加人类内皮细胞制备的一氧化氮释放。此外，羟基化的内比洛尔代谢物，包括但不限于4-羟基-6,6′-二氟-、4-羟基-5-酚-6,6′-二氟-和4-羟基-8-苯基-6,6′-二氟-，具有在慢性给药后增加人类内皮细胞释放一氧化氮能力的能力。本发明提供了羟基化的内比洛尔代谢物和包含内比洛尔和/或至少一种内比洛尔羟基化代谢物和/或至少一种用于治疗心血管疾病的其他化合物或其药学上可接受的盐的组合物。此外，本发明提供了通过给靶向受影响的血管疾病的部位至少给予一种能够释放治疗有效量一氧化氮的内比洛尔羟基化代谢物的方法来治疗和/或预防血管疾病的方法。此外，本发明还涉及通过至少给予一种内比洛尔羟基化代谢物来治疗和/或预防偏头痛。此发明还可与代谢综合征疾病的单个治疗或联合治疗一起使用。
• Compositions comprising nebivolol
  申请人：MYLAN LABORATORIES, INC

  公开号：EP2174658A1

  公开（公告）日：2010-04-14

  Described is the use of a safe and therapeutically effective amount of a combination of: (i) nebivolol or a pharmaceutically acceptable salt thereof; (ii) at least one hydralazine compound or a pharmaceutically acceptable salt thereof; and (iii) at least one of isosorbide dinitrate and/or isosorbide mononitrate; in the preparation if a medicament for improving NO release in a black patient, which results in reducing mortality associated with cardiovascular disease and improving exercise tolerance or the quality of life.

  描述了安全且治疗有效量的以下物质组合的用途：(i)奈必洛尔或其药学上可接受的盐；(ii)至少一种水拉嗪化合物或其药学上可接受的盐；和(iii)二硝酸异山梨酯和/或单硝酸异山梨酯中的至少一种；用于制备改善黑人患者 NO 释放的药物，从而降低与心血管疾病相关的死亡率，改善运动耐受性或生活质量。